Ana Bonetti Lugo, MD
Pulmonary Disease · Columbus, MSNPI 1285984005
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (49.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Intuitive Surgical at 51.1% of the total. 2025 is the largest year on record at $9,279, more than ten times the $630 reported in 2019.
Across 418 payments — averaging $34.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- AstraZeneca$2K
- GSK$1K
- Boehringer Ingelheim$680
- Sanofi$515
- Mallinckrodt Hospital Products Inc.$481
- plus $2K from 21 others
What the payments were for
- Travel & lodging$2252%
- Food & beverage$6,98149%
- Education$7,04449%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 11 | $7,281 |
| AstraZeneca | 89 | $1,618 |
| GSK | 106 | $1,342 |
| Boehringer Ingelheim | 40 | $680 |
| Sanofi | 30 | $515 |
| Mallinckrodt Hospital Products Inc. | 24 | $481 |
| Mylan Specialty L.p. | 14 | $295 |
| Philips North America LLC | 15 | $285 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $216 |
| Grifols USA, LLC | 10 | $198 |
| Bayer | 10 | $185 |
| Regeneron Healthcare Solutions, Inc. | 8 | $158 |
| Ceribell, Inc. | 1 | $128 |
| Insmed, Inc. | 7 | $122 |
| Merck | 6 | $96 |
| Abiomed | 3 | $93 |
| Viatris Specialty LLC | 4 | $73 |
| Novartis | 5 | $72 |
| Baxter Healthcare | 3 | $66 |
| Amgen | 4 | $64 |
| United Therapeutics Corporation | 4 | $62 |
| Verona Pharma, Inc. | 3 | $51 |
| Electromed, Inc. | 3 | $50 |
| Boston Scientific | 1 | $39 |
| Pfizer | 2 | $36 |
| AbbVie | 2 | $31 |
| Shire North American Group Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,250 in reported general payments places this provider in the 80th percentile of 101 pulmonary disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ActharCorticotropin | 12 | $538,362 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 526 | $338,940 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 303 | $216,844 |
| Dupixent PenDupilumab | 37 | $137,289 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 11 | $120,853 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 76 | $37,172 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 27 | $33,494 |
| Spiriva RespimatTiotropium Bromide | 39 | $26,563 |
| Breo ElliptaFluticasone/Vilanterol | 56 | $26,157 |
| SymbicortBudesonide/Formoterol Fumarate | 71 | $21,301 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 24 | $11,117 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 427 | $11,092 |
| Ventolin HfaAlbuterol Sulfate | 180 | $10,035 |
| DuleraMometasone/Formoterol | 26 | $9,408 |
| BreynaBudesonide/Formoterol Fumarate | 51 | $8,390 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $481 | $538,36212 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $1,342 | $402,269658 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,618 | $243,664387 claims |
| Grifols USA, LLCProlastin C | $198 | $120,85311 claims |
| Boehringer IngelheimCombivent Respimat, Spiriva Respimat, Stiolto Respimat | $680 | $71,17490 claims |
| MerckDulera | $96 | $9,40826 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 101 pulmonary disease providers in Mississippi.
Other pulmonary disease in Columbus
- Christopher RailwahColumbus$11K
- Ciro Rincon-PrietoColumbus$7K
- Yash SardaColumbus$4K
- William FrazierCanton$809K
- Demondes HaynesJackson$809K
- Bobby TullosGulfport$276K
- Michal SenitkoJackson$185K
- Cameron HuxfordStarkville$155K
- L AldredHattiesburg$76K
- Andrew WilhelmJackson$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.